SCHEMBL1875644

SCHEMBL1875644

NC(=O)[C@@H](CCF)NS(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 11/20 0.49
ADAMTS5 Q9UNA0 1/20 0.49
SLC1A3 P43003 1/20 0.49
SLC1A2 P43004 1/20 0.49
SLC1A1 P43005 1/20 0.49
MMP9 P14780 7/20 0.47
CA2 P00918 3/20 0.47
MMP1 P03956 3/20 0.47
MMP13 P45452 3/20 0.47
MMP8 P22894 3/20 0.47
CA1 P00915 2/20 0.47
CA12 O43570 2/20 0.47
CA9 Q16790 2/20 0.47
CA14 Q9ULX7 2/20 0.47
LMNA P02545 2/20 0.46
ALDH1A1 P00352 1/20 0.46
RECQL P46063 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1875539 0.91 MMP2 (0.50) MMP2ADAMTS5SLC1A3SLC1A2SLC1A1
SCHEMBL1876081 0.87 MMP2 (0.60) MMP2ADAMTS5SLC1A3SLC1A2SLC1A1
SCHEMBL310015 0.86 PSEN1 (0.48) MMP2ADAMTS5SLC1A3SLC1A2SLC1A1
SCHEMBL12502549 0.86 PSEN1 (0.48) MMP2ADAMTS5SLC1A3SLC1A2SLC1A1
SCHEMBL5794550 0.83 MMP2 (0.49) MMP2ADAMTS5SLC1A3SLC1A2SLC1A1
SCHEMBL1871538 0.80 MMP2 (0.53) MMP2ADAMTS5SLC1A3SLC1A2SLC1A1
SCHEMBL1879215 0.80 MMP2 (0.53) MMP2ADAMTS5SLC1A3SLC1A2SLC1A1
SCHEMBL1878137 0.80 MMP2 (0.49) MMP2ADAMTS5SLC1A3SLC1A2SLC1A1
SCHEMBL1874090 0.80 MMP2 (0.49) MMP2ADAMTS5SLC1A3SLC1A2SLC1A1
SCHEMBL5117214 0.78 MMP2 (0.74) MMP2ADAMTS5MMP9MMP1MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8513253-B2 α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-08-20 US disclosed
US-20110105485-A1 Alpha-(N-Sulfonamido)Acetamide Derivatives as Beta-Amyloid Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2011-05-05 US disclosed
US-20110105485-A1 Alpha-(N-Sulfonamido)Acetamide Derivatives as Beta-Amyloid Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2011-05-05 US disclosed
US-7786122-B2 α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2010-08-31 US disclosed
US-7786122-B2 α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2010-08-31 US disclosed
US-7786122-B2 α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2010-08-31 US disclosed
EP-1465861-B1 ALPHA-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2009-05-06 EP disclosed
EP-1465861-B1 ALPHA-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2009-05-06 EP disclosed
US-20080085894-A1 ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2008-04-10 US disclosed
US-20080085894-A1 ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2008-04-10 US disclosed
US-20080085894-A1 ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2008-04-10 US disclosed
US-7300936-B2 α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-11-27 US disclosed
US-7300936-B2 α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-11-27 US disclosed
US-7300936-B2 α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-11-27 US disclosed
EP-1465861-A4 ALPHA-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2005-12-07 EP disclosed
EP-1465861-A1 ALPHA-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS Bristol-Myers Squibb Company (US) 2004-10-13 EP disclosed
US-20040127494-A1 Alpha-(N-sulfonamido)acetamide derivatives as beta-amyloid inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-07-01 US disclosed
WO-2003053912-A1 α-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS β-AMYLOID INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085894-A1 ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS APP, APBA1, BACE1 MMP2 2676/4885ADAMTS5 4578/4885SLC1A3 710/4885
US-20110105485-A1 Alpha-(N-Sulfonamido)Acetamide Derivatives as Beta-Amyloid Inhibitors APP, APBA1, BACE1 MMP2 2676/4885ADAMTS5 4578/4885SLC1A3 710/4885
US-20040127494-A1 Alpha-(N-sulfonamido)acetamide derivatives as beta-amyloid inhibitors APBA1, APP, BACE1 MMP2 3016/4885ADAMTS5 4450/4885SLC1A3 406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.